Research Support
Enhancement of blood-brain barrier combination drug delivery for DMG/DIPG using an AI approach
Digital Pathology and AI for Biomarker Discovery in PNOC Clinical Trials
Enhance T-cell therapies for DIPG by developing improved cell-based immunotherapy, investigating CAR T cell persistence through manipulation of T cell negative regulators, and identifying key limitations using immune-competent mouse models.
![CN_Master_RGB_150ppi_Lg[2].png](https://static.wixstatic.com/media/5dd690_f5b0790fb504412c8477afde34d30951~mv2.png/v1/crop/x_0,y_35,w_350,h_113/fill/w_356,h_115,al_c,lg_1,q_85,enc_avif,quality_auto/CN_Master_RGB_150ppi_Lg%5B2%5D.png)
Map the genetics and epigenetics of DMG resistance to therapy by defining the cellular composition of treatment-resistant tumors, identifying gene regulators of resistance, and correlating these findings with clinical factors to determine biomarkers that will guide future clinical trials.
Enhance the efficacy and safety of DIPG treatment by using logic-gated CAR-T cells and combination therapies, expanding our understanding of optimizing these CARs against low-antigen expressing tumor cells.
The DMG-Act group, an international and multidisciplinary team, focuses on finding effective combination therapies for children with DIPG and DMG by elucidating drug mechanisms, generating robust efficacy data, and creating efficient pipelines to map drug targets and identify predictive biomarkers.
A Combination Therapy Trial using an Adaptive Platform Design for Children and Young Adults with Diffuse Midline Gliomas (DMGs) including Diffuse Intrinsic Pontine Gliomas (DIPGs) at Initial Diagnosis, Post-Radiation Therapy and at Time of Progression.
H3.3K27M Specific Peptide Vaccine Combined with poly-ICLC and Nivolumab for the Treatment of newly diagnosed HLA-A2 (02:01)+ H3.3K27M Positive Diffuse Intrinsic Pontine Glioma (DIPG) and newly diagnosed HLA-A2 (02:01)+ H3.3K27M Positive Midline Gliomas
MPF is a founding member of DIPG DMG Research Funding Alliance, a group of fifty plus families coming together to fund research, trial access and data integration or utilization.